Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Healthcare has been running neck and neck with energy and consumer discretionary for the worst sector of 2025.

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...